Guanqiao Li, M.D., Principal Investigator, Assistant Professor

Research Interests: drug evaluation and regulation, pharmacoepidemiology, real-world studies, digital health

Education

2009 - 2017  M.D., Clinical Medicine (8-year program), School of Medicine, Tsinghua University

2009 - 2012 B.Sc., Life Sciences, School of Life Sciences, Tsinghua University

Working Experience

2022.05 - Present Assistant Professor, Vanke School of Public Health, Tsinghua University

2019.11 - 2022.4 Assistant Researcher, Tsinghua Clinical Research Institute, School of Medicine, Tsinghua University

2017.10 - 2019.10 Postdoctoral Fellow, Tsinghua University-GlaxoSmithKline (GSK) Center of Global Health, Tsinghua University

2012.09 - 2014.07 Visiting Scholar, Hillman Cancer Center, University of Pittsburgh Medical Center, USA

Research

Dr. Li’s team utilizes pharmacoepidemiology methodologies, digital health technologies and multi-omics techniques to critically assess emerging issues and tools on the development, evaluation, regulation and use of therapeutics during clinical development and in real-world settings.

【Job opportunities: Dr Li’s lab welcomes applications from interested postdoctoral fellows and research assistants. Please contact guanqiaoli@tsinghua.edu.cn.】

Publication (selected)

Drug development, evaluation and regulation

1. Li G, Liu Y, Ruyi H, Su L, Chen X. (2022) FDA decisions on new oncologic drugs: China’s experience with imported drugs. Lancet Oncology;23(5):583-585.

2. Li G*, Liu Y*, Hu H, Yuan S, Zhou L, Chen X. (2022) Evolution of innovative drug R&D in China. Nat Rev Drug Discov. 21(8):553-554.

3. Li G, Jiang Y, Qin Y, Yuan S, Chen X. (2022) Comparing development strategies for PD-1/PD-L1-based immunotherapies. Nat Rev Drug Discov. 21(7):484.

4. Liu Y*, Zhang N*, Xie C, Jiang Y, Qin Y, Zhou L, Fan Y, Ren L, Yin C, Yang H, Xie W, Zhai Q, Li G#, Chen H#, Chen X#. (2022) Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharmaceutica Sinica B. August 2022 online.

5. Li G*, Liu Y*, Xie C, Zhou Q, Chen X. (2021) Characteristics of expedited programs on cancer drug approval in China. Nat Rev Drug Discov. 20(6):416.

6. Li G, Qin Y, Xie C, Wu Y, Chen X. (2021) Trends in oncology drug innovation in China. Nat Rev Drug Discov. 20(1): 15-16.

7. Bai X, Jiang S, Zhou Y, Zhen H, Ji J, Li Y, Ruan G, Yang Y, Shen K, Wang L, Li G#, Yang H#. (2021) Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 12:720776. (# corresponding authors)

8. Li G, Liu X, Chen X. (2020) Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 17(10):589-590.

9. Li G*, Yin C*, Zhou Y, Wang T, Chen J, Liu Y, Chen T, Wang H, Zhang L, Chen X. (2020) Digitalized Adaptation of Oncology Trials during and after COVID-19. Cancer Cell. 38(2):148-149.

10. Li G, Sachdev U, Peters K, Liang X, Lotze MT. (2019) The VE-PTP inhibitor AKB-9778 improves anti-tumor activity and diminishes toxicity of Interleukin 2 (IL-2) administration. J Immunother.42:237-243

Public health and epidemiology

1. Li G, Jiang Y, Zhang L. (2019) HIV upsurge in China's students. Science. 364(6442):711.

2. Ge C*, Du K*, Luo M, Shen K, Zhou Y, Guo K, Liu Y, Yin C, Li Y, Li G#, Chen X# (2022). Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol. 2022;11(1):46. (# corresponding authors)

3. Li G*, Zhou Y*, Ji J, Liu X, Jin Q, Zhang L. (2021) Surging publications on the COVID-19 pandemic. Clin Microbiol Infec.;27(3):484-486.

4. Lv Y*, Li G*, Hu M*, Xu C*, Lu H*, Xing Y, Liang S, Ma Y, Liang S, Zhuang M, Li Y, Huang C, Bai Y, Jiang Y#, Zhang L#. (2021) Anonymous linkage between college students and facilities: systematic evaluation of urine self-collection for HIV testing initiative in China. Clin Infect Dis.;73(5):e1108-e1115.

5. Chen T*, Huang S*, Li G*, Zhang Y, Zhu J, Shi X, Li X#, Xie G#, Zhang L#. (2021) An integrated framework for modelling quantitative effects of entry restrictions and travel quarantine on importation risk of COVID-19. J Biomed Inform. 118:10380

6. Sun K*, Xu L*, Li G*, Ruan X, Li X, Deng P, Li X, Li Q, Chen X, Xiong Y, Lu S, Qi L, Shen C, Tang W, Rong R, Hong B, Ning Y, Long D, Xu J, Shi X, Yang Z, Zhang Q, Zhuang Z, Zhang L#, Xiao J#, Li Y#. (2019) Forecasting Influenza Activity Using Self-Adaptive AI Model and Multi-Source Data in Chongqing, China. Ebiomedicine.47:284-292.